이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AnGes 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ei Yamada

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	21.8yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.3yrs

최근 관리 업데이트

Recent updates

CEO

Ei Yamada (74 yo)

21.8yrs

테뉴어

Dr. Ei Yamada, Ph D., M.D., serves as Director at Emendo Bio, Inc. He has been the President and Chief Executive Officer of AnGes MG Inc since September 2002. Dr. Yamada has been the Chief Executive Office...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ei Yamada	CEO, President & Representative Director	22.8yrs	데이터 없음	0.045% ¥ 4.6m
Naoya Sato	Director of Corporate Development & Director	2.3yrs	데이터 없음	데이터 없음
Makoto Hara	External Independent Director	6.3yrs	데이터 없음	데이터 없음
Junichi Komamura	External Independent Director	12.3yrs	데이터 없음	데이터 없음
Naoyuki Ono	Standing Corporate Auditor	3yrs	데이터 없음	데이터 없음
Norikazu Eiki	External Independent Director	10.1yrs	데이터 없음	데이터 없음
Kimiko Murofushi	External Independent Director	2.3yrs	데이터 없음	데이터 없음
Katsunori Horikoshi	Corporate Auditor	7yrs	데이터 없음	데이터 없음
Koichi Ando	Corporate Auditor	3.3yrs	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

74yo

평균 연령

경험이 풍부한 이사회: 4563 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.

AnGes 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

AnGes, Inc., Annual General Meeting, Mar 28, 2024

AnGes, Inc., Annual General Meeting, Mar 30, 2023

No independent directors

No independent directors

AnGes, Inc., Annual General Meeting, Mar 30, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Recent updates

AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)

AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024

AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe

New major risk - Share price stability

Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)

AnGes, Inc., Annual General Meeting, Mar 28, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

New minor risk - Market cap size

AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)

AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.

New major risk - Share price stability

AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding

AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)

Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)

AnGes, Inc., Annual General Meeting, Mar 30, 2023

AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

No independent directors

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

AnGes, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)

AnGes, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)

No independent directors

AnGes, Inc. to Report Q1, 2022 Results on May 10, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

New 90-day low: JP¥1,156

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. to Report Fiscal Year 2020 Results on Feb 15, 2021

AnGes, Inc. (TSE:4563) completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.

AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey

AnGes, Inc. to Report Q3, 2020 Results on Oct 26, 2020

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령